Final figures for 2016 confirm good year-end results, says Stada Arz

German generic drugmaker Stada Arzneimittel (SAZ: Xetra), currently evaluating various takeover approaches, has reported that group sales for 2016 increased by 1% to 2.14 billion euros ($2.29 billion). Adjusted to currency and portfolio effect, sales increased 3% to 2.17 billion euros.

The earnings situation in the reporting year was shaped by special items – by expenses in connection with reorganization decisions in particular – and totaled 116.7 million euros before and 91.4 million euros after taxes, said Stada.

Reported operating profit leapt 20% to 178.1 million euros. Adjusted operating profit increased 4% to 294.4 million euros. Reported earnings before interest, taxes, depreciation and amortization (EBITDA) showed an increase of 2% to 398.0 million euros. Reported earnings per share fell to 1.38 euros from 1.79 euros the previous year, though adjusted EPS increased to 2.85 euros, up from 2.69 euros.